Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986500 in Advanced Solid Tumors and Breast Cancer
NCT06997029Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1 trial of BMS-986500 in solid tumor, breast cancer and ovarian cancer (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
BMS-986500
03
Conditions
solid tumorbreast cancerovarian cancer
Beyond the preview
Go deeper on NCT06997029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997029.